Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
A pediatric patient is reported who experienced fatal progressive pulmonary fibrosis as a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy. The patient received a cumulative dosage of 1.29 g (1.72 g/m2) over a two-year period as adjuvant therapy for a medulloblastoma. Two and one-half years after cessation of therapy, cough, tachypnea and fatigue were noted. Progressive pulmonary insufficiency developed. Pulmonary pathologic findings included interstitial fibrosis and alveolar dysplasia. Other cases of BCNU pulmonary toxicity are cited from the medical literature.
D001932:Brain Neoplasms / Q000188:drug therapy; D002330:Carmustine / Q000009:adverse effects*; D002675:Child, Preschool; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D012306:Risk
D002330:Carmustine